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Introduction: Neuropsychiatric symptoms in patients with frontotemporal dementia
(FTD) are highly prevalent and may complicate clinical managements.
Objective: To test whether the Neuropsychiatry Inventory (NPI) could detect change
in neuropsychiatric symptoms and caregiver’s distress in patients diagnosed with
behavioral variant frontotemporal dementia (bvFTD) and Alzheimer’s disease (AD) from
baseline to a 12-month follow-up and to investigate possible predictors of change in
NPI scores.
Methods: The sample consisted of 31 patients diagnosed with bvFTD and 28 patients
with AD and their caregivers. TheMini-Mental State Examination (MMSE), Addenbrooke’s
Cognitive Examination Revised (ACE-R), the INECO Frontal Screening (IFS), the Frontal
Assessment Battery (FAB), the Executive Interview (EXIT-25) and the NPI were applied.
Descriptive statistics, Mann-Whitney U test,Wilcoxon test, Chi square (χ2) test and Linear
Regression Analysis were used.
Results: NPI total and caregiver distress scores were statistically higher among bvFTD
patients at both assessment points. MMSE, ACE-R scores significantly declined and NPI
Total and Distress scores significantly increased in both groups. In the bvFTD group, age
was the only independent predictor variable for the NPI total score at follow up. In the
AD group, ACE-R and EXIT-25, conjunctively, were associated with the NPI total score
at follow up.
Conclusions: In 12 months, cognition declined and neuropsychiatric symptoms
increased in bvFTD and AD groups. In the AD group only, cognitive impairment was
a significant predictor of change in neuropsychiatric symptoms.
Keywords: neuropsychiatric symptoms, behavioral dementia frontotemporal (bvFTD), Alzheimer’s disease (AD),
elderly, aging
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INTRODUCTION
Behavioral variant frontotemporal dementia (bvFTD) is a
neurodegenerative syndrome which is usually diagnosed in
midlife (mean age at onset around 58 years). Prevalence peaks in
the early sixties, at about 13 cases per 100,000 individuals. Among
the frontotemporal dementias, bvFTD is the most common one
as it represents 50% of the cases (1).
The diagnosis of bvFTD is a challenging one, mainly in the
initial stage of the disease, when its clinical expression is limited
to personality and behavioral changes (2). Close inspection of
behavioral changes could support accurate differential diagnosis
from psychiatric diseases and other dementias (3).
In bvFTD, identifying neuropsychiatric symptoms and
following them up over time is relevant for treatment and disease
management, as they may relate to the progressive decline in
social and emotional functions. The frequency and intensity of
such symptoms may alsohelp to distinguish bvFTD from other
disorders. For instance, during bvFTD course, apathy can be the
most frequent and intense symptom (2, 4).
In a previous study from our group (5), the most frequently
reported symptoms among bvFTD patients were apathy (present
in 85% of this patient group), irritability (65%), disinhibition
(60%) and agitation/aggression (55%). Among patients with
AD, depression (67%) and anxiety (63%) were most frequently
reported. Those findings were in line with those from Riedijk
et al. (6) and de Vugt et al. (7).
In a comparison between patients with bvFTD and
Alzheimer’s disease (AD), Kumfor et al. (8) reported that
60% of AD patients and 84% of bvFTD patients had apathy,
and it was more severe and frequent in bvFTD patients. Besides,
bvFTD patients presented higher affective and cognitive apathy,
while AD patients presented only higher cognitive apathy.
Findings on affective apathy were related to changes in the
ventral prefrontal cortex areas, behavioral apathy was related to
the basal ganglia and cognitive apathy was related to changes
in the dorsomedial prefrontal cortex. In addition, the authors
pointed out that care burden is an expected outcome of affective
and behavioral apathy in bvFTD patients (8).
Clinical studies with follow-up data regarding
neuropsychiatric symptoms in bvFTD and possible predictors
of change are lacking (9). Therefore, we investigated whether
there was significant change in neuropsychiatric symptoms
and caregivers’ distress in patients with bvFTD and AD, from
baseline to the 12-month follow-up. We also investigated if there
were associations between sociodemographic variables, cognitive
performance and neuropsychiatric symptoms at both assessment
points. This study is particularly important to describe clinical
symptoms along the disease course in bvFTD and AD aiming to




Questions about age, sex, and years of education were answered
by the caregivers.
Cognitive Assessment
University-based neurology outpatient services databases were
queried, and patients and their family caregivers were recruited
for the study. Specialized dementia centers across three Brazilian
universities were involved: the Cognitive and Behavioral
Neurology Group (GNCC-SP) and the Program for the Elderly
(PROTER) at the University of São Paulo; the Cognitive
and Behavioral Neurology Group (GNCC-MG) at the Federal
University of Minas Gerais and the Department of Neurology at
the State University of Campinas (UNICAMP).
Participants
A total of 59 individuals, comprising 28 diagnosed with AD
and 31 with bvFTD, were included in the study. Patients with
bvFTD and with AD were matched for disease severity
on the Clinical Dementia Rating scale–frontotemporal
lobar degeneration [CDR-FTLD, (10, 11)], with scores
from 0 to 3.
The diagnosis of bvFTD and AD was performed by
neurologists, geriatricians and psychiatrists, based on clinical,
neurological history, neuropsychological assessments and
screening for reversible causes of dementia along with laboratory
and neuroimaging exams: functional Magnetic Resonance
Imaging (fMRI) and Fluorodeoxyglucose PET (FDG-PET
patterns). Dementia was diagnosed based on the criteria from
the Diagnostic and Statistical Manual 5th Edition [DSM-V,
(12)]. International diagnostic criteria were employed for
diagnosing probable bvFTD (13). The National Institute on
Aging - Alzheimer’s Association (NIA/AA) criteria were used for
AD diagnosis McKhann et al., (14).
Inclusion criteria for patients were age ≥ 40 years, education
> 2 years and the presence of an informant who was involved
in the daily routine of the patient (formal or informal carer;
usually spendingmore than 8 h/day with the patient). Individuals
presenting with visual, auditory or motor deficits preventing
them from understanding instructions or performing cognitive
tasks, individuals with other uncontrolled clinical diseases
(such as hypertension and diabetes), serious and debilitating
psychiatric disorders such as major depression, schizophrenia,
bipolar disorder, clinical evidence or neuroimaging exam
findings suggestive of vascular problems, dementias or etiologies
other than bvFTD or AD, were excluded.
General cognition was assessed with the MMSE (0–30
points) [Folstein, (15)], (16) and the Addenbrooke’s Cognitive
Examination-Revised (ACE-R) [Mioshi et al., (17)], (18) (0–
100 points).
Executive functions were assessed with the INECO Frontal
Screening (IFS) (0–30 points), the Frontal Assessment
Battery (FAB) (0–18 points) and the Executive Interview
(EXIT-25) (0–50 points). The IFS items assess: response
inhibition and set shifting [motor programming, conflicting
instructions, go-no go test, verbal inhibitory control (Modified
Hayling test)], abstraction (proverb interpretation) and,
working memory (backward digit span, verbal working
memory and spatial working memory). The IFS generates
a separate score for working memory which varies from
0 to 9 (19, 20). The FAB is comprised of six subtests
Frontiers in Neurology | www.frontiersin.org 2 September 2021 | Volume 12 | Article 728108
Da Silva et al. Neuropsychiatric Symptoms in bvFTD and AD
which assess conceptualization, mental flexibility, motor
programming, sensitivity to interference, inhibitory
control, and environmental mastery (21, 22). The EXIT-
25 assesses verbal fluency, design fluency, anomalous
sentence repetition, sensitivity to interference, among others
(23, 24).
Neuropsychiatric Symptoms
The NPI assesses neuropsychiatric symptoms commonly
found in dementia. It evaluates 12 domains (delusion,
hallucinations, dysphoria, anxiety, agitation/aggression,
euphoria, disinhibition, irritability/emotional lability, apathy,
aberrant motor activity, night-time behavioral disturbances
and appetite and eating abnormalities); thus yielding a
composite symptom domain score (total score) (frequency
× severity) ranging from 0 (absence of behavioral symptoms)
to 144 points (maximum severity of behavioral symptoms)
(25). The scale for assessing caregiver distress has scores
ranging from 0 to 5 points (0 = no distress; 1 = minimal
distress; 2 = mild distress; 3 = moderate distress; 4 = severe
distress; and 5 = extreme distress) and the total distress
score (NPI Distress) is calculated as the sum of the scores for
each symptom.
Statistical Analyses
Initially, all quantitative variables (continuous and discrete) were
analyzed using the Kolmogorov-Smirnov test to assess whether
or not they followed a normal distribution. The absence of
normal distribution was observed in most quantitative variables,
so non-parametric tests were used: Chi-square (x2) test, Mann-
Whitney U test and Wilcoxon test.
The Mann-Whitney U test was used, at different times, to
compare bvFTD vs. AD groups. To analyze the differences
between baseline and the 12-month follow up within the
same clinical group, the Wilcoxon test was used. To analyze
the influence of sociodemographic and cognitive variables on
the NPI scores, linear regression analysis was used, with
a multivariate model, and stepwise forward criteria for the
selection of independent variables (age, gender, years of
education, MMSE, ACER, EXIT-25, IFS, FAB), from the simplest
to the most complex model (26).
The computer program Statistica 7.0 was used. The level
of significance adopted for the statistical tests was 5%, that is,
p-value < 0.05.
Procedures and Ethical Aspects
This study was approved by the Ethics Committee of the Hospital
das Clínicas, protocol number 311.601. The study was conducted
in compliance with international ethical standards, according to
the Declaration of Helsinki.
RESULTS
The demographic and clinical characteristics of the patients are
presented in Table 1. At baseline, 29 men (49.15%) and 30
women (50.85%) were included in the study. The mean age was
70.29± 9.85 years (range 50–87 years).
TABLE 1 | Demographic and clinical characteristics of patients diagnosed with
Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD).
Characteristics bvFTD (n = 31) AD (n = 28)
Mean SD Mean SD p-value
Women n (%) 13 (41.90%) 17 (60.71%) 0.195a
Age (range: 50–87) 66.94 9.26 74.15 9.22 0.004b
Schooling (0–21 Years) 11.74 4.57 9.43 4.49 0.055b
Clinical characteristics
MMSE (Baseline) 23.61 4.96 23.35 3.54 0.397b
MMSE (1 Year) 22.50 4.69 22.87 3.91 0.775b
0.005c 0.043c
ACER (Baseline) 71.71 16.36 67.57 11.77 0.173b
ACER (1 Year) 69.32 15.54 66.61 11.51 0.563b
0.001c 0.028c
EXIT-25 (Baseline) 14.96 9.36 12.43 7.82 0.353b
EXIT-25 (1 Year) 16.74 10.28 12.90 9.04 0.256b
0.028c 0.753c
IFS (Baseline) 15.42 6.35 16.41 5.06 0.973b
IFS (1 Year) 15.02 6.34 16.06 5.13 0.942b
0.423c 0.108c
FAB (Baseline) 12.42 4.07 13.75 2.69 0.607b
FAB (1 Year) 12.35 4.02 13.60 2.74 0.386b
1.00c 1.00c
NPI Total (Baseline) 45.58 23.85 25.64 16.92 0.001b
NPI Total (1 Year) 47.90 22.88 28.36 19.46 0.001b
0.008c 0.043c
NPI Distress (Baseline) 19.16 10.19 12.29 8.20 0.007b




cWilcoxon Matched Pairs Test.
AD, Alzheimer’s disease; bvFTD, behavioral variant frontotemporal dementia; MMSE,
Mini Mental State Examination; ACE-R, Addenbrooke’s Cognitive Examination-Revised;
EXIT-25, Executive Interview with 25 items; IFS, INECO Frontal Screening; FAB, Frontal
Assessment Battery.
Patients with AD were significantly older than the patients
with bvFTD. MMSE and ACE-R scores decreased significantly
from baseline to follow-up in both clinical groups. EXIT-25
scores significantly declined for the bvFTD group only, indicating
that the executive dysfunction may have increased over time in
this group. IFS and FAB scores remained unchanged for both
groups (Table 1). NPI Total and Caregiver Distress scores were
significantly higher for the bvFTD group at both assessment
times. For both clinical groups, NPI Total and Distress scores
significantly increased from baseline to follow up.
For a better graphical display of the NPI results, a radar chart
was used (Figure 1). In this type of chart, the value axes start from
a common center. For this study, the vertical main axis represents
the 12 dimensions of the NPI. A line connects the score obtained
in each assessment, forming a polygon. The scores obtained
at baseline and at follow-up by different groups can be easily
compared by looking at the area of the 12-sided polygon. The
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FIGURE 1 | Frequency (%) of patients with neuropsychiatric symptoms (baseline and 1-year follow-up) for each clinical group.
larger the area of the polygon, the higher the reported symptoms.
The shape of the polygon is also relevant, since asymmetries
indicate that there are differences in the investigated domains.
When the clinical groups were compared at baseline,
significant differences emerged, as higher scores can be seen
for the bvFTD group for: agitation, eating disturbances and
disinhibition (Figure 1; Table 2), the latter two were also
observed in the NPI Distress subdomains (Table 3).
The groups were significantly different at baseline and follow-
up, with higher scores for the bvFTD group, in NPI agitation,
disinhibition, and eating disturbances, see Figure 1 and Table 2.
For NPI hallucination and irritability significant differences
between the groups emerged only at follow up. For the NPI
distress, hallucinations, agitation and eating disturbances scores
were significantly higher for the bvFTD group at follow up
(Table 3).
We did not find significant correlations between NPI data
and cognitive variables. However, using the Linear Regression
Analysis, as seen in Tables 4, 5, age was the only independent
predictor variable for the NPI Total score in the bvFTD Group in
the follow up. And in the AD group, ACE-R and EXIT-25 (follow-
up) were associated with the NPI Total score in the follow-up.
DISCUSSION
The aim of the present study was to test the hypothesis that
there was significant change in neuropsychiatric symptoms,
assessed by the NPI, in patients with bvFTD and AD, from
baseline to the 12-month follow-up. We also investigated if there
were changes in the NPI Caregiver Distress score and explored
potential links between sociodemographic variables, cognitive
performance and neuropsychiatric symptoms at baseline and
follow-up. The groups were statistically similar in terms of
sex, education, cognitive and functional assessment scores. The
mean age was higher in the AD group. The clinical groups
differed from the start in terms of NPI Total and Distress scores
(bvFTD > AD).
In the present study, after 12 months, both groups presented
with a reduction in MMSE and ACE-R scores and an increase
in the NPI Total and Distress scores. An increase in executive
dysfunction was also observed, according to the EXIT-25 scores,
in the bvFTD group.
Neuropsychiatric symptoms (NPI Total and Distress scores)
were statistically higher among bvFTD patients. Separately,
agitation, disinhibition and eating disorders symptoms were
higher in the bvFTD group, at baseline and follow-up
assessments. Hallucination, agitation and irritability were higher
in bvFTD at follow-up assessment in NPI Distress. These data
confirm previous studies results (27, 28) as they indicate higher
severity of NPI symptoms in bvFTD than in AD.
Not many studies have looked at differences between
dementia subtypes in clinic-based samples using the NPI. In
the first study that looked at differences in the NPI between
AD and bvFTD, disinhibition, euphoria, apathy and aberrant
motor behavior were found to be significantly higher in FTD
(29). The same differences were noted in an Italian sample of
patients with AD and FTD [Leroi et al., (30)]. Mendez et al. (31)
had also observed higher scores for FTD patients in the verbal
outbursts and inappropriate activity subscales of the BEHAVE-
AD rating scale, while AD patients had higher scores on the
affective disturbance and anxieties/phobias subscales.
In a recent study, with bvFTD, AD patients, and primary
progressive aphasia (PPA) patients, Radakovic et al. (32) used
the Dimensional Apathy Scale (DAS), which assesses: executive,
emotional and initiation apathy. A total of 12 patients with
PPA, 12 with bvFTD, and 28 with AD, and their caregivers (or
relatives and close friends) answered the DAS and the apathy
subtype awareness was obtained by the caregivers, to assess the
discrepancy rate. There was higher emotional apathy and lower
awareness for emotional apathy in bvFTD patients than in AD
patients (32).
Liu et al. (28) suggested that neuropsychiatric symptoms
are significant predictors of institutionalization (28). In bvFTD,
patients’ caregivers seem to experience higher levels of burden
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TABLE 2 | Mean neuropsychiatric inventory scores reported by caregivers for
each symptom.
Characteristics bvFTD (n = 31) AD (n = 28)
Mean SD Mean SD p-value
Delusions Baseline 0.84 2.45 0.11 0.57 0.192a
1 year 0.97 2.51 0.14 0.76 0.108a
1.000b 1.000b
Hallucinations Baseline 1.00 2.61 0.21 1.13 0.105a
1 year 1.26 2.74 0.29 1.51 0.032a
1.000b 1.000b
Agitation Baseline 6.03 4.61 3.21 4.55 0.031a
1 year 6.61 4.43 3.32 4.72 0.009a
1.000 b 0.789b
Depression Baseline 2.90 3.62 2.18 3.57 0.245a
1 year 3.29 3.87 2.00 3.33 0.119a
0.248b 1.000b
Anxiety Baseline 4.32 4.17 4.00 4.32 0.693a
1 year 4.58 4.07 3.68 4.27 0.356a
1.000b 1.000b
Euphoria Baseline 2.81 3.99 1.21 2.50 0.148a
1 year 2.58 3.82 1.54 2.89 0.322a
1.000b 1.000b
Apathy Baseline 6.29 4.41 4.32 4.15 0.103a
1 year 6.35 4.32 4.75 4.30 0.187a
1.000b 1.000b
Disinhibition Baseline 5.13 4.54 2.18 3.75 0.005a
1 year 5.16 4.56 3.04 4.10 0.044a
1.000b 0.109b
Irritability Baseline 5.00 4.37 2.89 3.93 0.075a
1 year 5.29 4.27 3.04 4.04 0.042a
1.000 b 0.789b
Aberrant motor behavior Baseline 2.94 4.11 1.50 2.56 0.333a
1 year 3.26 4.07 2.04 3.28 0.311a
1.000b 0.109b
Sleep disturbances Baseline 2.77 3.66 1.29 3.03 0.056a
1 year 2.84 3.66 1.93 3.70 0.230 a
1.000b 1.000b
Eating disturbances Baseline 5.45 4.20 2.46 3.49 0.007a
1 year 5.71 3.97 2.75 3.92 0.005a
1.000b 1.000b
aMann-Whitney U Test.
bWilcoxon Matched Pairs Test.
and suffering than AD patients’ caregivers do. Neuropsychiatric
symptoms seem to be associated with greater burden and
suffering in bvFTD patients’ caregivers, as observed in the present
study and previous ones (2, 5).
There is limited information regarding the trajectory of
neuropsychiatric symptoms over time in AD and bvFTD.
Present results suggest there was significant worsening in
NPI (Total and Distress) in both groups. For some NPI
domains, group differences reached significance at follow
up, with worse scores in the bvFTD group, which suggests
TABLE 3 | Mean neuropsychiatric inventory distress reported by caregivers for
each domain.
Characteristics bvFTD (n = 31) AD (n = 28)
Mean SD Mean SD p-value
Delusions Baseline 0.35 0.98 0.07 0.38 0.209a
1 year 0.42 1.03 0.14 0.76 0.121a
1.000b 1.000b
Hallucinations Baseline 0.45 1.21 0.11 0.57 0.111a
1 year 0.55 1.29 0.18 0.94 0.034a
1.000b 1.000b
Agitation Baseline 2.55 1.80 1.54 2.03 0.074a
1 year 2.81 1.70 1.50 1.99 0.018a
1.000b 1.000b
Depression Baseline 1.58 1.73 1.00 1.52 0.188a
1 year 1.68 1.72 0.89 1.47 0.069a
1.000b 1.000b
Anxiety Baseline 1.84 1.61 1.61 1.64 0.620a
1 year 2.06 1.59 1.50 1.64 0.205a
1.000b 1.000b
Euphoria Baseline 1.06 1.55 0.75 1.38 0.380a
1 year 0.94 1.46 0.82 1.39 0.730a
1.000b 1.000b
Apathy Baseline 2.52 1.81 2.29 1.80 0.700a
1 year 2.55 1.77 2.43 1.77 0.881a
1.000b 1.000b
Disinhibition Baseline 2.16 1.92 1.18 1.87 0.023a
1 year 2.19 1.96 1.61 2.02 0.172a
1.000b 0.109b
Irritability Baseline 1.97 1.68 1.46 1.79 0.317a
1 year 2.03 1.64 1.50 1.86 0.248a
1.000b 0.789b
Aberrant motor behavior Baseline 1.10 1.56 0.96 1.62 0.676a
1 year 1.26 1.57 1.04 1.62 0.527a
1.000b 1.000b
Sleep disturbances Baseline 1.29 1.70 0.54 1.20 0.062a
1 year 1.32 1.76 0.82 1.49 0.248a
1.000b 1.000b
Eating disturbances Baseline 2.23 1.65 0.75 1.29 0.001a
1 year 2.29 1.60 0.82 1.42 0.001a
1.000b 1.000b
aMann-Whitney U Test.
bWilcoxon Matched Pairs Test.
changes in NPI scores were of higher magnitude in this
group. These results, in a short follow up period, suggest
that it is relevant to track changes in neuropsychiatric
symptoms over time, to better caregivers regarding care
challenges. Higher emotional overload may be present in
bvFTD patients’ caregivers, due to behavior and personality
changes, as assessed with the NPI scale (5). Additionally,
studies have reported the difficulty of caregivers of patients
with bvFTD in managing day-to-day cognitive and behavioral
impairments (33).
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TABLE 4 | Linear regression analysis for NPI total score (baseline and 1-year
follow-up) among bvFTD patients.
Dependent variable Independent variables Beta Std.Err. p-level
NPI Total (baseline)a Age −0.330 0.197 0.107
NPI Total (1 Year)b Age −0.464 0.200 0.030
Schooling −0.209 0.200 0.306
aR = 0.330, R2 = 0.108, Adjusted R2 = 0.070; F(1, 23) = 2.810 p < 0.107 Std. Error of
estimate: 23.089.
bR = 0.445, R2 = 0.199, Adjusted R2 = 0.127, F(2, 22) = 2.7453 p < 0.086 Std. Error of
estimate: 21.467. Dependent variables: Total NPI (baseline and follow-up). Independent
variables: sex (1 = woman; 0 = man), age, education, MMSE, ACER, EXIT-25, IFS, FAB.
TABLE 5 | Linear regression analysis for NPI total score (baseline and 1-year
follow-up) among AD patients.
Dependent variable Independent variables Beta Std. Err. p-level
NPI Total (baseline)a Schooling −0.283 0.266 0.307
NPI Total (1 Year)b ACE-R Total −0.623 0.290 0.045
EXIT-25 −0.658 0.289 0.035
aR = 0.283, R2 = 0.080, Adjusted R2 = 0.009, F(1, 13) = 1.131 p < 0.307 Std. Error of
estimate: 17.119.
bR = 0.494, R2 = 0.244, Adjusted R2 = 0.159, F(2, 18) = 0.904 p < 0.080 Std. Error of
estimate: 17.947. Dependent variables: Total NPI (baseline and follow-up). Independent
variables: sex (1 = woman; 0 = man), age, education, MMSE, ACER, EXIT-25, IFS, FAB.
Finally, we highlight that neuropsychiatric symptoms in AD
only were associated with cognitive scores in the regression
analyses. This finding may perhaps be explained by the fact
that cognitive impairment is a core symptom in AD since
the early disease stages and, therefore, cognition may drive
neuropsychiatric symptoms.
As to study limitations, we cite that the present study was
based on relatively small samples, and this may have hindered
the identification of group differences of small magnitude. As to
its strengths, we indicate the inclusion of a follow up assessment.
Due to the epidemiological significance of bvFTD, further
research studies on the clinical characterization of the disease
course are needed. Research studies with larger samples,
including different dementia subtypes, examining the links
between cognitive performance, neuropsychiatric symptoms and
caregiver burden are recommended.
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